Biochem Pharma (BCHE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jean-Robert Grenier who wrote (495)	10/16/1998 4:53:00 PM
From: Richard Haugland	Read Replies (2) of 783

Jean-Robert: a post that followed on Yahoo felt that the analysis was completely wrong messages.yahoo.com@m2.yahoo.com Here was my personal analysis of the financial effect of BCHE collecting royalties on extra sales of lamivudine for hepatitis made the day of the announcement: messages.yahoo.com@m2.yahoo.com It seems to me that 17% royalty of anything that Glaxo sells mostly goes to bottom line so that even if the sales are only half a billion dollars (US) in a few years it will have a strong positive effect on the stock's price (unless BCHE compensates by spending more money for research and/or acquisitions). I am not qualified to comment on Glaxo's pricing strategy in developing countries and it is probably a dilemma for them too.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next